Management of poor-prognosis or relapsed germ-cell cancer
Author:
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2009.08865.x/fullpdf
Reference62 articles.
1. International Germ Cell Classification: a prognostic factor-based staging system for metastatic germ-cell cancers;International Germ Cell Collaborative Group.;J Clin Oncol,1997
2. Recent advances in management of patients with platinum-refractory testicular germ cell tumors;Kollmannsberger;Cancer,2006
3. Randomized study of cisplatin dose intensity in poor risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology group protocol;Nichols;J Clin Oncol,1991
4. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study;Nichols;J Clin Oncol,1998
5. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study;Kaye;J Clin Oncol,1998
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors;Canadian Urological Association Journal;2023-11-20
2. High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres;BJU International;2022-03-31
3. Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report;Journal of Medical Case Reports;2017-04-11
4. Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial;Journal of Cancer;2011
5. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients;Bone Marrow Transplantation;2010-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3